These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2051976)

  • 1. [Specific antitumor effect of lymphokine-activated lymphocytes obtained from tumor-bearing mice after intratumoral injection of interleukin-2 (IL-2)].
    Takahashi M
    Nihon Geka Gakkai Zasshi; 1991 Mar; 92(3):247-56. PubMed ID: 2051976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intratumoral injection of biological response modifier (BRM)].
    Nishiyama K
    Nihon Geka Gakkai Zasshi; 1991 Sep; 92(9):1225-8. PubMed ID: 1944192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvest.
    Lafreniere R; Borkenhagen K; Bryant LD; Ng E
    J Biol Response Mod; 1989 Jun; 8(3):238-51. PubMed ID: 2787392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
    Cao X; Wang Q; Ju DW; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity.
    Forni G; Giovarelli M; Santoni A; Modesti A; Forni M
    J Immunol; 1987 Jun; 138(11):4033-41. PubMed ID: 2953796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
    Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
    Spiess PJ; Yang JC; Rosenberg SA
    J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice.
    Fuyama S; Yamamoto H; Arai S
    Cancer Res; 1985 Sep; 45(9):4103-8. PubMed ID: 3875404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.
    Murphy WJ; Back TC; Conlon KC; Komschlies KL; Ortaldo JR; Sayers TJ; Wiltrout RH; Longo DL
    J Clin Invest; 1993 Oct; 92(4):1918-24. PubMed ID: 8408644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Nocardia rubra cell wall skeleton on T-cell-mediated cytotoxicity in mice bearing syngeneic sarcoma.
    Kawase I; Uemiya M; Yoshimoto T; Ogura T; Hirao F; Yamamura Y
    Cancer Res; 1981 Feb; 41(2):660-6. PubMed ID: 6969630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.